# A Phase 1a/1b Study of ELVN-001 for the Treatment Chronic Myeloid Leukemia

> **NCT05304377** · PHASE1 · RECRUITING · sponsor: **Enliven Therapeutics** · enrollment: 250 (estimated)

## Conditions studied

- Chronic Myeloid Leukemia
- Chronic Phase Chronic Myeloid Leukemia, BCR-ABL1 Positive
- Cml

## Interventions

- **DRUG:** ELVN-001

## Key facts

- **NCT ID:** NCT05304377
- **Lead sponsor:** Enliven Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-05-22
- **Primary completion:** 2027-12
- **Final completion:** 2027-12
- **Target enrollment:** 250 (ESTIMATED)
- **Last updated:** 2026-04-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05304377

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05304377, "A Phase 1a/1b Study of ELVN-001 for the Treatment Chronic Myeloid Leukemia". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05304377. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*